Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19172077 | Methods of administering safe colon cleansing compositions | April 2025 | December 2025 | Allow | 8 | 1 | 0 | No | No |
| 19062757 | Methods of administering safe colon cleansing compositions | February 2025 | August 2025 | Allow | 6 | 1 | 0 | No | No |
| 18792849 | Methods of administering safe colon cleansing compositions | August 2024 | February 2025 | Allow | 7 | 1 | 0 | No | No |
| 18743526 | Methods of administering safe colon cleansing compositions | June 2024 | December 2024 | Allow | 7 | 2 | 0 | Yes | No |
| 18711575 | INTRAVITREAL CORTICOSTEROID EXTENDED RELEASE IMPLANT AND METHODS OF USE | May 2024 | May 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18665291 | COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA, MILD HYPEROPIA, AND IRREGULAR ASTIGMATISM | May 2024 | October 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18659629 | AQUEOUS LIQUID PREPARATION | May 2024 | January 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18654817 | KETOROLAC COMPOSITIONS FOR CORNEAL WOUND HEALING | May 2024 | July 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18654308 | VETERINARY PHARMACEUTICAL COMPOSITIONS FOR DIRECT SYSTEMIC INTRODUCTION | May 2024 | August 2025 | Allow | 16 | 1 | 0 | No | No |
| 18633608 | SYSTEMS AND METHODS FOR APPLICATION OF ACTIVE INGREDIENTS TO CANNABIS | April 2024 | July 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18425024 | GRANULATED AGRICULTURAL ADJUVANT AND METHOD OF MAKING AND USING SAME | January 2024 | January 2025 | Allow | 11 | 1 | 0 | No | No |
| 18360372 | GEL BASE COMPOSITION FOR COMPOUNDING INTO A MUCOADHESIVE DELIVERY SYSTEM | July 2023 | April 2025 | Abandon | 21 | 3 | 0 | Yes | No |
| 18336958 | TOBACCO LEAF FOLIAR SPRAYING SUBSTANCE AND METHOD FOR REDUCING HARMFUL INGREDIENTS IN CHEROOT AND TOBACCO SHREDS | June 2023 | March 2024 | Allow | 9 | 2 | 0 | No | No |
| 18189284 | SYSTEMS AND METHODS FOR APPLICATION OF ACTIVE INGREDIENTS TO CANNABIS | March 2023 | June 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18177018 | TREATING NEUROPATHIC PAIN IN SPINAL CORD INJURED INDIVIDUALS | March 2023 | February 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18006277 | PROCESS FOR MAKING AN ISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | January 2023 | February 2026 | Allow | 36 | 2 | 0 | No | No |
| 18148421 | LENSES FOR TREATING OCULAR DISEASES AND PREPARATION METHOD THEREOF | December 2022 | March 2026 | Allow | 38 | 1 | 1 | No | No |
| 18075161 | INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY | December 2022 | March 2026 | Allow | 39 | 2 | 0 | No | No |
| 18054951 | PHARMACEUTICAL COMPOSITION FOR CORNEAL TISSUE REPAIR BY INSULIN NANOSYSTEM AND USE THEREOF | November 2022 | October 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17986092 | FORTIFIED NUTRITIONAL LUBRICATING DROPS FOR DRY EYE DISEASE | November 2022 | July 2025 | Allow | 32 | 2 | 1 | No | No |
| 17985058 | DIVALENT METAL-CONTAINING BIOMATERIALS AND METHODS OF USE | November 2022 | May 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17981922 | IRON COMPLEXES OF ESTERIFIED DERIVATIVES OF NATURAL PRODUCTS, AND METHODS OF USE | November 2022 | September 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17973639 | COMPOSITION FOR PROMOTING THE GROWTH OF LEGUMES | October 2022 | November 2025 | Allow | 37 | 1 | 0 | No | No |
| 17968113 | USE OF TT-10-LOADED NANOPARTICLES FOR CARDIAC REPAIR | October 2022 | October 2024 | Abandon | 24 | 1 | 0 | No | No |
| 18045059 | COMPOSITIONS AND METHODS FOR ENHANCING WNT SIGNALING FOR TREATING CANCER | October 2022 | May 2025 | Allow | 31 | 2 | 1 | Yes | No |
| 17995071 | A STERILIZATION PROCESS OF TIMOLOL GEL FORMING SOLUTION THROUGH ASEPTIC FILTRATION | September 2022 | July 2025 | Allow | 34 | 1 | 0 | No | No |
| 17951986 | USE OF 4-(PHENYLETHYNYL) BENZOIC ACID | September 2022 | March 2024 | Allow | 18 | 2 | 0 | No | No |
| 17935065 | Low Viscosity Agricultural Adjuvant for Spraying Syrups and Method of Production | September 2022 | May 2024 | Allow | 20 | 1 | 0 | No | No |
| 17950612 | NOVEL CERIUM OXIDE NANOCOMPLEX AND A COMPOSITION FOR PREVENTING OR TREATING LIVER FAILURE COMPRISING THE SAME | September 2022 | August 2024 | Allow | 23 | 3 | 0 | No | No |
| 17933929 | COMPOSITIONS AND USES OF ALPHA-ADRENERGIC AGENTS | September 2022 | April 2025 | Allow | 31 | 1 | 0 | No | No |
| 17903597 | Ocular surface drug retention agent, eye drop containing the same, and method for retention of ocular surface drug using the same and method for treating ocular disease | September 2022 | June 2024 | Allow | 21 | 2 | 0 | Yes | No |
| 17907953 | NEW USE AND METHOD OF TREATMENT | August 2022 | February 2026 | Allow | 41 | 2 | 0 | No | No |
| 17876811 | PHOTOCURABLE HYDROGEL LOADED WITH VH298-MODIFIED EXOSOME AND METHOD OF PREPARATION AND USE THEREOF | July 2022 | May 2024 | Allow | 22 | 1 | 0 | No | No |
| 17873751 | UNCONJUGATED PLGA NANOPARTICLES IN THE TREATMENT OF ALZHEIMER'S DISEASE | July 2022 | October 2025 | Abandon | 38 | 3 | 0 | No | No |
| 17860886 | INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY | July 2022 | February 2026 | Abandon | 43 | 2 | 0 | No | No |
| 17846344 | Early Applications of Encapsulated Acetamides for Reduced Injury in Crops | June 2022 | October 2025 | Allow | 40 | 4 | 1 | No | No |
| 17787603 | COMPOSITION FOR PREVENTING OR TREATING OCULAR DISEASES COMPRISING AMNIOTIC EPITHELIAL CELL DERIVED EXOSOMES | June 2022 | May 2025 | Allow | 35 | 1 | 0 | No | No |
| 17787159 | THIENYLOXAZOLONES AND ANALOGUES | June 2022 | August 2025 | Allow | 38 | 1 | 0 | No | No |
| 17785019 | COMPOSITION COMPRISING HYALURONIC ACID-BASED POLYION COMPLEX PARTICLE | June 2022 | August 2025 | Allow | 38 | 1 | 1 | No | No |
| 17833019 | APPLICATION OF ENDOPHYTIC FALCIPHORA ORYZAE FO-R20 IN CONTROLLING PANICLE BLAST | June 2022 | February 2024 | Allow | 21 | 1 | 0 | No | No |
| 17781991 | USE OF DATE SACCHARIDES ONLY OR IN ADMIXTURE WITH POLYPHENOLS TO PROTECT PLANTS AGAINST PATHOGENS | June 2022 | November 2025 | Abandon | 42 | 2 | 0 | No | No |
| 17829427 | FRESHENING COMPOSITION COMPRISING BACTERIAL SPORES | June 2022 | December 2025 | Allow | 43 | 5 | 0 | No | No |
| 17744665 | AN ENDOPHYTIC MAGNAPORTHIOPSIS INCRUSTANS M-B927 AND ITS APPLICATION | May 2022 | September 2025 | Allow | 40 | 1 | 1 | No | No |
| 17776168 | STAINLESS STEEL CAN FOR PRESSURISED METERED DOSE INHALERS | May 2022 | January 2026 | Allow | 44 | 1 | 1 | No | No |
| 17736456 | Hygiene Product Pod and Methods of Using Same | May 2022 | October 2025 | Allow | 41 | 1 | 0 | No | No |
| 17658643 | MICRONUTRIENT-CONTAINING BIOSTIMULANT COMPOSITION | April 2022 | August 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17767804 | AGROCHEMICAL COMPOSITION | April 2022 | April 2025 | Allow | 36 | 1 | 0 | No | No |
| 17658644 | PHYTOREGULATOR FOR PLANTS | April 2022 | April 2025 | Abandon | 37 | 3 | 0 | No | No |
| 17754531 | NON-DEGRADABLE EMBOLISATION MICROSPHERE | April 2022 | November 2025 | Allow | 43 | 1 | 1 | No | No |
| 17656825 | Zeaxanthin Formulations With Additional Ocular-Active Nutrients, For Protecting Eye Health And Treating Eye Disorders | March 2022 | February 2025 | Abandon | 35 | 2 | 0 | No | No |
| 17702885 | GERMINATION/SPROUTING AND FRUIT RIPENING REGULATORS | March 2022 | September 2024 | Allow | 30 | 2 | 1 | No | No |
| 17642191 | HIGHLY EFFECTIVE FORMULATIONS ON THE BASIS OF 2-[(2,4-DICHLORPHENYL)-METHYL]-4,4'-DIMETHYL-3-ISOXAZOLIDINONES AND PREEMERGENCE HERBICIDES | March 2022 | July 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17753196 | Biostimulant agent for treating plants and/or plant seed | February 2022 | September 2025 | Allow | 43 | 1 | 1 | No | No |
| 17636651 | SYNERGISTIC HPPD MIXTURES | February 2022 | June 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17635579 | COMPOSITIONS AND METHODS RELATING TO INSECTICIDES | February 2022 | August 2025 | Allow | 42 | 2 | 1 | No | No |
| 17671060 | BIOERODIBLE OCULAR DRUG DELIVERY INSERT AND THERAPEUTIC METHOD | February 2022 | October 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17634994 | XANTHOPHYLL COMPOSITION COMPRISING LUTEIN AND ZEAXANTHIN WITH ENHANCED BIOAVAILABILITY | February 2022 | November 2025 | Allow | 45 | 3 | 0 | No | No |
| 17634980 | BACTERIA AND METHODS OF USE THEREOF | February 2022 | November 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17632152 | AQUEOUS FORMULATION THAT REDUCES DAMAGE CAUSED BY SPRING FROSTS IN PLANTS AND PRODUCTION METHOD THEREOF | February 2022 | February 2024 | Allow | 24 | 1 | 0 | No | No |
| 17649469 | RHEOLOGY MODIFIED LOW FOAMING LIQUID ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF | January 2022 | November 2024 | Allow | 33 | 2 | 0 | No | No |
| 17630521 | ARTHROBACTER PASCENS X-1 FOR PROMOTING GROWTH OF NODULES AND INCREASING ABUNDANCE OF PROBIOTIC MICROORGANISM POPULATIONS | January 2022 | February 2026 | Abandon | 48 | 1 | 1 | No | No |
| 17597823 | Methods and Compositions of the Botanical Extract to Promote and Boost Plant Growth and Prevent and Suppress Plant Diseases | January 2022 | September 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17582886 | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy | January 2022 | January 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17629267 | PROCESS FOR THE PREPARATION OF STERILE OPHTHALMIC AQUEOUS FLUTICASONE PROPIONATE FORM A NANOCRYSTALS SUSPENSIONS | January 2022 | April 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17580770 | Seed Coating | January 2022 | October 2024 | Allow | 33 | 3 | 0 | No | No |
| 17627341 | HERBICIDAL COMPOUNDS | January 2022 | July 2025 | Allow | 42 | 1 | 1 | No | No |
| 17626313 | MIXTURES COMPRISING INDAZOLE PESTICIDES | January 2022 | May 2025 | Allow | 40 | 1 | 1 | No | No |
| 17622677 | USE OF DIHYDROPORPHIN DERIVED FROM CHLOROPHYLL AS PLANT GROWTH REGULATOR | December 2021 | December 2024 | Allow | 36 | 2 | 0 | No | No |
| 17622631 | PLANT DISEASE CONTROL AGENT AND PLANT DISEASE CONTROL METHOD | December 2021 | December 2025 | Abandon | 48 | 3 | 0 | Yes | No |
| 17622576 | MELANOIDIN COMPOSITIONS FOR PROTECTING CROPS FROM NONFUNGAL PESTS | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17619311 | STABLE HERBICIDAL COMPOSITIONS COMPRISING AMINE OXIDE AND BETAINE | December 2021 | June 2025 | Allow | 42 | 1 | 1 | No | No |
| 17619565 | PHARMACEUTICAL COMPOSITION COMPRISING A COLLOIDAL DISPERSION AND METHODS AND USES THEREOF | December 2021 | February 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17618931 | FORMULATIONS AND METHODS FOR CONTROLLING INVASIVE AMPHIBIANS | December 2021 | April 2025 | Allow | 40 | 2 | 0 | No | No |
| 17618531 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS | December 2021 | May 2025 | Allow | 41 | 1 | 1 | No | No |
| 17617788 | SYNERGISTICALLY EFFECTIVE FUNGICIDE COMPOSITION COMPRISING CHOLINE PHOSPHONATE AND AT LEAST ONE ADDITIONAL FUNGICIDE | December 2021 | August 2025 | Allow | 44 | 2 | 0 | No | No |
| 17533862 | PROCESSES AND COMPOSITIONS FOR INCREASING ENZYME CONCENTRATIONS AND DRY MATTER USING REACTIVE OXYGEN SPECIES IN HYDROPONICALLY GROWN CELLULOSIC MATERIALS | November 2021 | March 2025 | Abandon | 40 | 3 | 0 | No | No |
| 17612551 | Vancomycin Liposome Compositions and Methods | November 2021 | March 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17529305 | OLEIC ACID-RELEASING CONTACT LENS | November 2021 | July 2025 | Allow | 44 | 2 | 2 | No | No |
| 17525170 | HIGH-PURITY THERMOSTABLE CRYSTAL FORM OF SUBSTITUTED 3-ISOXAZOLIDINONE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | November 2021 | September 2024 | Allow | 34 | 1 | 0 | No | No |
| 17610263 | HERBICIDAL COMPOSITION | November 2021 | December 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17595080 | HIGH SPREADING ULV FORMULATIONS FOR HERBICIDES | November 2021 | February 2026 | Abandon | 51 | 3 | 0 | No | No |
| 17516845 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | November 2021 | November 2024 | Allow | 36 | 1 | 0 | No | No |
| 17507593 | PRESERVATIVE REMOVAL FROM EYE DROPS | October 2021 | September 2024 | Allow | 35 | 2 | 0 | No | No |
| 17505029 | Methods and Compositions for Treating Ulcerative Colitis | October 2021 | December 2024 | Allow | 38 | 2 | 0 | No | No |
| 17604892 | ESTERS OF NON- AROMATIC HETEROCYCLIC COMPOUNDS HAVING A NEMATOCIDAL ACTIVITY, THEIR AGRONOMIC COMPOSITIONS AND USE THEREOF | October 2021 | May 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17501854 | SUPER-RESOLUTION OPTICAL MICROSCOPY USING ALUMINOSILICATE NANOPARTICLES | October 2021 | August 2024 | Allow | 34 | 1 | 1 | No | No |
| 17491687 | PEROXIDE-LESS BIOPHOTONIC COMPOSITIONS AND METHODS | October 2021 | December 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17600897 | PYRIDAZINONE COMPOUND AND HERBICIDE | October 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17598467 | A DELIVERY SYSTEM COMPRISING SILICON-CONTAINING MATERIAL | September 2021 | July 2025 | Allow | 46 | 1 | 1 | No | No |
| 17486308 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLURBIPROFEN | September 2021 | May 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17593749 | SUBSTITUTED 2-HETEROARYLAMINOBENZENES AND THE SALTS THEREOF AND THEIR USE AS HERBICIDAL AGENTS | September 2021 | May 2025 | Allow | 44 | 2 | 1 | No | No |
| 17441722 | METHOD FOR CONTROLLING WEEDS | September 2021 | November 2024 | Allow | 38 | 1 | 0 | No | No |
| 17441748 | METHOD FOR CONTROLLING WEEDS | September 2021 | February 2025 | Allow | 41 | 2 | 0 | No | No |
| 17442027 | COMPOSITION FOR KIDNEY TREATMENT USING OMENTUM, A MEDICAL KIT FOR KIDNEY TREATMENT, INCLUDING THE SAME, AND FILM FOR KIDNEY TREATMENT, INCLUDING CURED PRODUCT THEREOF | September 2021 | August 2025 | Abandon | 46 | 3 | 0 | Yes | No |
| 17593615 | FRUIT BLOSSOM END ROT-PREVENTING AGENT COMPRISING NITROPHENOL COMPOUND OR SALT THEREOF | September 2021 | May 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17448151 | Facile Assembly of Soft Nanoarchitectures and Co-Loading of Hydrophilic and Hydrophobic Molecules via Flash Nanoprecipitation | September 2021 | August 2024 | Allow | 35 | 1 | 0 | No | No |
| 17439455 | Aqueous 1,2-Benzisothiazoline-3-One Dispersions | September 2021 | September 2024 | Allow | 36 | 1 | 0 | No | No |
| 17438871 | NOVEL 3-(2-BROMO-4-ALKYNYL-6-ALKOXYPHENYL)-3-PYRROLIN-2-ONES AND THEIR USE AS HERBICIDES | September 2021 | January 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17593100 | SOIL MICROBIAL REGULATOR FOR ENHANCING PLANT STRESS RESISTANCE | September 2021 | December 2024 | Allow | 39 | 2 | 0 | No | No |
| 17465748 | Solid Implant Formulation for Drug Delivery | September 2021 | November 2024 | Abandon | 38 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FAY, ZOHREH ALEMZADEH.
With a 21.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 24.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner FAY, ZOHREH ALEMZADEH works in Art Unit 1617 and has examined 407 patent applications in our dataset. With an allowance rate of 66.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 25 months.
Examiner FAY, ZOHREH ALEMZADEH's allowance rate of 66.6% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by FAY, ZOHREH ALEMZADEH receive 2.00 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by FAY, ZOHREH ALEMZADEH is 25 months. This places the examiner in the 78% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a -7.0% benefit to allowance rate for applications examined by FAY, ZOHREH ALEMZADEH. This interview benefit is in the 4% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 21.5% of applications are subsequently allowed. This success rate is in the 26% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 45.9% of cases where such amendments are filed. This entry rate is in the 70% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 44.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 48.1% of appeals filed. This is in the 13% percentile among all examiners. Of these withdrawals, 69.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 80.7% are granted (fully or in part). This grant rate is in the 85% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 34.7% of allowed cases (in the 96% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.